These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9591518)

  • 1. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
    Chase TN
    Neurology; 1998 May; 50(5 Suppl 5):S17-25. PubMed ID: 9591518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neostriatal mechanisms in Parkinson's disease.
    Chase TN; Oh JD; Blanchet PJ
    Neurology; 1998 Aug; 51(2 Suppl 2):S30-5. PubMed ID: 9711978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous dopaminergic stimulation in early and advanced Parkinson's disease.
    Stocchi F; Olanow CW
    Neurology; 2004 Jan; 62(1 Suppl 1):S56-63. PubMed ID: 14718681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
    Schwartz M; Sabetay S
    Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
    Oh JD; Chase TN
    Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of dopaminergic agents in Parkinson's disease.
    Koller WC; Rueda MG
    Neurology; 1998 Jun; 50(6 Suppl 6):S11-4; discussion S44-8. PubMed ID: 9633680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.
    Olanow CW; Obeso JA; Stocchi F
    Lancet Neurol; 2006 Aug; 5(8):677-87. PubMed ID: 16857573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
    Chase TN; Oh JD
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Levodopa for Parkinson's disease: What have we learned?].
    Juri C C; Chaná C P
    Rev Med Chil; 2006 Jul; 134(7):893-901. PubMed ID: 17130974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
    Mouradian MM; Chase TN
    Exp Neurol; 1997 Mar; 144(1):51-7. PubMed ID: 9126152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
    Olanow CW; Stocchi F
    Neurology; 2004 Jan; 62(1 Suppl 1):S72-81. PubMed ID: 14718683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor fluctuations in levodopa treatment: clinical pharmacology.
    Stocchi F; Bonamartini A; Vacca L; Ruggieri S
    Eur Neurol; 1996; 36 Suppl 1():38-42. PubMed ID: 8791020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.